U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H23NO5.ClH.H2O
Molecular Weight 399.866
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRETOQUINOL HYDROCHLORIDE MONOHYDRATE

SMILES

O.Cl.COC1=CC(C[C@@H]2NCCC3=C2C=C(O)C(O)=C3)=CC(OC)=C1OC

InChI

InChIKey=NYRVBYLXLHGXDP-UTLKBRERSA-N
InChI=1S/C19H23NO5.ClH.H2O/c1-23-17-7-11(8-18(24-2)19(17)25-3)6-14-13-10-16(22)15(21)9-12(13)4-5-20-14;;/h7-10,14,20-22H,4-6H2,1-3H3;1H;1H2/t14-;;/m0../s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: http://www.situsobat.com/2014/04/inolin-tablet-3-mg.html www.drugfuture.com/mt/tretoquinol-hydrochloride.pdf

Trimetoquinol hydrochloride dilates bronchial muscle selectively by stimulating Beta 2-receptors. It is used for the relief of bronchoconstriction associated with bronchitis, asthmatic bronchitis and bronchial asthma. Since the concurrent use of the drug with catecholamines such as Epinephrine and Isoproterenol may induce arrythmia or cardiac arrest in some cases, concurrent use is not recommended. Adverse reactions : Palpitation may occur occasionally, and alteration of blood pressure and precordial pain may appear rarely; headache may occur occasionally; tremor, dizziness, feverish sensation may also be encountered in a rare incidence; occasionally, nausea and anorexia may appear.

Originator

Yamato, E.|Hirakura, M.|Sugasawa S.
3
Curator's Comment: Mitsubishi Tanabe Pharma Corporation transferred the marketing rights of Inolin (Ingredient – Trimetoquinol) to its subsidiary, Tanabe Seiyaku Hanbai Co.Ltd at April 1, 2011. http://www.mt-pharma.co.jp/e/release/nr/2011/pdf/e_110307.pdf

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2678
 7.34 null [pKi]
Agonist
2678
 6.49 null [pKi]
Agonist
2678
 5.43 null [pKi]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8429
Inolin

Approved Use

It is given as the bronchodilating agent in the management of reversible airways obstruction, as in asthma.
Chronic obstructive pulmonary disease
174
Sources: www.drugfuture.com/mt/tretoquinol-hydrochloride.pdf
 Palliative
Approved
8429
Inolin

Approved Use

It is given as the bronchodilating agent in the management of reversible airways obstruction, as in chronic obstructive pulmonary disease.
Palliative
Approved
8429
Inolin

Approved Use

It is used to treat chronic bronchitis.
PubMed

PubMed

TitleDatePubMed
Intravenous and intratracheal administration of trimetoquinol, a fast-acting short-lived bronchodilator in horses with 'heaves'.
2006 Nov
The effect of botulinum toxin type A on full-face intense pulsed light treatment: a randomized, double-blind, split-face study.
2008 Aug
Plasma and urinary concentrations of trimetoquinol by LC-MS-MS following intravenous and intra-tracheal administration to horses with heaves.
2008 Dec
[Yersinia psuedotuberculosis septicemia in a healthy young woman].
2008 Mar
Eyelid localization in mantle cell lymphoma: long-lasting complete remission after surface brachytherapy.
2009 May-Jun
Errors in opioid prescribing: a prospective survey in cancer pain.
2010 Apr

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Intravenous and intratracheal administration of trimetoquinol are tested also: http://www.ncbi.nlm.nih.gov/pubmed/17124848 http://www.ncbi.nlm.nih.gov/pubmed/17124848 http://www.ncbi.nlm.nih.gov/pubmed/963963 http://www.ncbi.nlm.nih.gov/pubmed/971582
3-12 mg per day (in 2-3 separate doses)
Route of Administration: Oral
In Vitro Use Guide
Pre-incubation of platelet microsomes with Trimethoquinol (10-100 ug/ml) for up to 4 min didn’t suppress production of Thromboxane A2-like activity.
Name Type Language
TRETOQUINOL HYDROCHLORIDE MONOHYDRATE
Common Name English
TRETOQUINOL HYDROCHLORIDE HYDRATE
JAN  
Common Name English
NSC-288748
Code English
TRIMETOQUINOL HYDROCHLORIDE HYDRATE [JAN]
Common Name English
6,7-ISOQUINOLINEDIOL, 1,2,3,4-TETRAHYDRO-1-((3,4,5-TRIMETHOXYPHENYL)METHYL)-, HYDROCHLORIDE, MONOHYDRATE, (S)-
Systematic Name English
VEMS
Brand Name English
TRIMETOQUINOL HYDROCHLORIDE
Common Name English
TRETOQUINOL HYDROCHLORIDE HYDRATE [JAN]
Common Name English
Tretoquinol hydrochloride [WHO-DD]
Common Name English
(-)-1,2,3,4-TETRAHYDRO-1-(3,4,5-TRIMETHOXYBENZYL)ISOQUINOLINE-6,7-DIOL HYDROCHLORIDE MONOHYDRATE
Systematic Name English
INOLIN
Brand Name English
TRETOQUINOL HYDROCHLORIDE
MART.   WHO-DD  
Common Name English
TRETOQUINOL HYDROCHLORIDE [MART.]
Common Name English
RO-07-5965
Code English
TRIMETOQUINOL HYDROCHLORIDE HYDRATE
JAN  
Common Name English
Trimetoquinol hydrochloride hydrate [WHO-DD]
Common Name English
AQ-110
Code English
TRIMETHOQUINOL HYDROCHLORIDE MONOHYDRATE
Common Name English
Code System Code Type Description
EPA CompTox
DTXSID10222852
Created by admin on Fri Dec 15 18:25:43 GMT 2023 , Edited by admin on Fri Dec 15 18:25:43 GMT 2023
PRIMARY
NSC
288748
Created by admin on Fri Dec 15 18:25:43 GMT 2023 , Edited by admin on Fri Dec 15 18:25:43 GMT 2023
PRIMARY
FDA UNII
SS28YGI1ZQ
Created by admin on Fri Dec 15 18:25:43 GMT 2023 , Edited by admin on Fri Dec 15 18:25:43 GMT 2023
PRIMARY
SMS_ID
100000077521
Created by admin on Fri Dec 15 18:25:43 GMT 2023 , Edited by admin on Fri Dec 15 18:25:43 GMT 2023
PRIMARY
CAS
72534-66-8
Created by admin on Fri Dec 15 18:25:43 GMT 2023 , Edited by admin on Fri Dec 15 18:25:43 GMT 2023
PRIMARY
EVMPD
SUB15598MIG
Created by admin on Fri Dec 15 18:25:43 GMT 2023 , Edited by admin on Fri Dec 15 18:25:43 GMT 2023
PRIMARY
ChEMBL
CHEMBL299175
Created by admin on Fri Dec 15 18:25:43 GMT 2023 , Edited by admin on Fri Dec 15 18:25:43 GMT 2023
PRIMARY
PUBCHEM
23724963
Created by admin on Fri Dec 15 18:25:43 GMT 2023 , Edited by admin on Fri Dec 15 18:25:43 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of TRETOQUINOL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966